eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Pfizer Limited

Ramsgate Road, Sandwich, Kent, CT13 9NJ
Telephone: +44 (0)1304 616 161
Fax: +44 (0)1304 656 221

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 22/06/2007
SPC Feldene Gel

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/06/2007 and displayed until Current
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 17/05/2007 and displayed until 22/06/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 1 -Name of the Medicinal product
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Pending awaiting re-submission
Date of revision of text on the SPC:   02/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.2 – undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control the symptoms

4.3 – addition of severe heart failure

4.4 – same statement as above for 4.2, expanded precautions & warnings for patients with CV risk

4.8addition of adverse events hypertension & cardiac failure, clinical trial & epidemiological data suggest that some NSAIDs may be associated with a small increased risk of arterial thrombotic events

In addition, reference to Feldene Dispersible tablets has been removed from sections 1-4.2, 5.1, 5.2, 6.1, 6.3-6.5, 8 & 9.

Updated on 21/07/2003 and displayed until 17/05/2007
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
Updated on 20/07/2001 and displayed until 21/07/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 20/07/2001 and displayed until 20/07/2001
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
  • Change to section 10 (date of (partial) revision of the text
Updated on 19/07/2001 and displayed until 20/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 04/02/2000 and displayed until 19/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 04/02/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   piroxicam